Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial

CONCLUSIONS: Tislelizumab plus lenvatinib demonstrated promising antitumor activity with favourable tolerability as first-line therapy for patients with uHCC.TRIAL REGISTRATION: ClinicalTrials.gov (NCT04401800).PMID:38650037 | DOI:10.1186/s12916-024-03356-5

Source: Cancer Control - April 22, 2024 Category: Cancer & Oncology Authors: Li Xu Jinzhang Chen Chang Liu Xiaoling Song Yanqiao Zhang Haitao Zhao Sheng Yan Weidong Jia Zheng Wu Yabing Guo Jiayin Yang Wei Gong Yue Ma Xiaobo Yang Zhenzhen Gao Nu Zhang Xin Zheng Mengyu Li Dan Su Minshan Chen Source Type: research